Vivek Subbiah: Such A Delight To Attend The 2026 The ASCO Post Advisory Board Meeting
Vivek Subbiah/Linkedin

Vivek Subbiah: Such A Delight To Attend The 2026 The ASCO Post Advisory Board Meeting

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:

“Such a delight to attend the 2026 The ASCO Post Advisory Board meeting at American Society of Clinical Oncology (ASCO) Annual meeting ASCO 26 in Chicago!

  •  It is the #1 oncology newspaper in the field (source: Kantar Media).
  •  Fantastic discussion on what goes into ASCO Post & how to share the greatest updates in oncology. Incredible teamwork spearheaded by Jame Abraham, Cara Glynn , and the amazing team lead by Dr. James O. Armitage.

Photo credit: Matt Herp.”

Other articles featuring Vivek Subbiah on OncoDaily.